Fluorodopa (FDOPA) is an analogue of L-di hydroxyphenylalanine (L-dopa) used to assess the nigro striatal dopamine system in vivo with positron emission tomography (PET). However, FDOPA/PET quantitation is complicated by the presence of the 3-0-methyl-FDOPA (30MFD) fraction in brain and plasma. Pretreatment with entacapone (OR-6 11), a peripheral catechol O-methyl transferase (COMT) inhibitor, greatly reduces the plasma 30MFD fraction and provides an ideal situation to eval uate the contribution of the plasma 30MFD fraction in several kinetic models of FDOPA uptake. We performed FDOPA/PET with and without the OR-6 11 preadminis tratiolll in six Parkinson's disease (PD) patients. We mea sured the time-course of the plasma FDOPA and 30MFD fractions using high-pressure liquid chromatography (HPLC). We calculated striato-occipital ratios (SOR), and estimated the striatal FDOPA uptake rate constant graphically using the plasma FDOPA and occipital tissue Parkinson's disease (PD) is characterized by pre synaptic nigrostriatal dopamine dysfunction. L-di-Rec,
time activity curves (KtD and KjO CC , respectively). We also estimated striatal dopa decarboxylase (DDC) activity (k] D) using a model incorporating independent measure ments of 30MFD transport kinetic rate constants. With the preadministration of OR-611, the pharmacological ef ficiency in plasma was prolonged significantly (21.1-37.7%; p < 0.0 1). We also observed significant mean el evations in SOR and KjO CC by 21.8 and 53.5%, respec tively (p < 0.05). KtD and k] D did not show significant change. We conclude that OR-611 prolongs the circula tion time of FDOP A in the plasma but does not alter rate constants for striatal FDOP A uptake or decarboxylation. hydroxyphenylalanine (L-dopa) remains the single most effective agent for the presynaptic treatment of PD (Cedarbaum et aI., 1991) . L-dopa is a large neutral amino acid (LNAA) that enters the brain via a carrier transport mechanism shared with other LNAAs (Oldendorf and Szabo, 1976; Morris, 1978; Nutt and Fellman, 1984; Leenders et aI., 1986) . In the brain, L-dopa is taken up by presynaptic dopa minergic terminals and converted to dopamine by the enzyme L-aromatic amino acid decarboxylase, or dopa decarboxylase (DDC) (Lloyd et aI., 1975) . When DDC is inhibited, L-dopa in the circulation is largely converted into catechol-O-methyldopa (30MD) by catechol-O-methyltransferase (COMT) (Nutt and Fellman, 1984) . Due to this O-methyl ation, only a small fraction of orally administered levodopa « 1 0%) actually reaches the brain, even when there is maximal inhibition of decarboxylase (Mannisto and Kaakkola, 1989) .
Methods for improving the bioavailability of L-dopa may help to prolong its anti parkinsonian ef fect. In this regard, there has been much interest in several new COMT inhibitors as adjuncts to L-dopa therapy (Backstrom et a!., 1989) Of these, OR-611 (OR-61l) appears to have utility in the treatment of L-dopa-related response fluctuations by blocking peripheral COMT activity (Linden et aI . , 1990; Mannisto et aI., 1992; Kaakkola et aI., 1994) .
6-[ '8 F]fluoro-L-dopa (FDOPA) is an analogue of L-dopa used to assess the presynaptic nigrostriatal dopamine system in vivo with positron emission to mography (PET). This method yields quantitative information on regional differences in FDOPA en try and metabolism in the brain . However, the ki netic analysis of FDOPA uptake is complicated by the presence of 3-0-methyl-FD01PA (30MFD) frac tion in the brain (G�edde et aI., 1991; Huang et aI., 1991; Kuwabara et aI., 1993) . Peripheral inhibition of 30MFD formation with COMT inhibitors pro vides an ideal situation to assess the contribution of the plasma 30MFD fraction in the kinetic models that have been developed to estimate striatal DDC activity. Several groups have reported the effect of COMT inhibition on striatal FDOPA uptake. Gutt man et a!. (1993) administered OR-6Il to cynomol gus monkeys and found that striatal FDOPA accu mulation showed a 2.3-fold increase, with no signif icant change in kinetic rate constants for FDOPA transport and decarboxylation. found that OR-611 preadministration elevated the target-to-background ratio as well as striatal FDOPA uptake rate constants estimated with the use of tissue input function.
In this study, we performed FDOPA/PET to as sess the effects of OR-611 on the systemic metabo lism and striatal uptake of FDOPA using a compre hensive kinetic model (Dhawan e1: a!. , 1996) . These results were compared with those obtained through the model of Kuwabara et al. (1993) to evaluate the sensitivity of each to the plasma 30MFD fraction.
MATERIALS AND METHODS

Subjects
We studied six patients (one woman and five men; mean ± SD age, 57.7:c 13.6 years) with mild-to-moderate parkinsonism: Hoehn and Yahr stage I, four patients; Hoehn and Yahr stages II and Ill, one patient each (Hoehn and Yahr, 1967) . Ethical permission for these studies was obtained fmm the InstitutIOnal Review Board of North Shore University HospitaliCornell University Medical College. Written Informed consent for all sub-jects was obtained following a detailed explanation of the scanning procedure.
PET
PET studies were performed using Superpett 3000 to mograph (Scanditronix; Essex, MA, U.S.A.). The perfor mance characteristics of this instrument have been de scribed elsewhere (Robeson et aI., 1993) . This four-ring BaF2 time-of-flight, whole body tomograph acquires 14 PET slices with Z-axis gantry translation of one half-ring distance every 30 s. Each slice is 8-mm thick and recon structed with an in-plane resolution of 7.5 mm-full width at half maximum (FWHM)-in high resolution mode.
Each patient was studied with FDOPAIPET on two occasions at least 1 week apart. In each study, patients fasted overnight prior to PET scanning. All anti parkin so nian medications were discontinued at least 12 h before PET investigations. All patients received 200 mg carbi dopa 90 min before the study to inhibit decarboxylation. At each scanning session, patients were randomly as signed an additional premedication, either OR-611 (400 mg) or placebo, 60 min before the study. Those who re ceived OR-611 in the first study were given placebo in the second, and vice versa.
Patients were positioned in the scanner using the Laiti nen stereoadapter (Hariz and Erikson, 1986) with three dimensional laser alignment with reference to the orbito meatal line. A cylindrical tube filled with 68Ge was placed in the field of view to provide real-time calibration for each slice. All studies were performed with eyes open in a dimly lit room and minimal auditory stimulation. FDOP A was produced according to the radiochemical synthesis of Luxen et al. (1990) , and was> 95% radio chemically pure. Then, 260-370 MBq (7-10 mCi) of FDOPA in 20-25 ml saline was injected into an antecu bital vein over 45 s with an automated infusion pump. The transit time from injection point to the brain (brain delay) was measured by the coincidence counter on the scanner. Emission scanning began simultaneously with the start of the FDOPA injection, and continuous scan data were ac quired in list mode between 0 and 100 min postinjection. PET images were reconstructed with a correction for tis sue attenuation of 511 KeV gamma-radiation measured with an external 68Ge source. PET reconstructions were also corrected for random coincidence, electronic dead time, and scatter effects.
The time course of plasma 18F radioactivity was deter mined by radial arterial blood sampling followed by plasma centrifugation. Sixteen 9-s samples were taken by a precision peristaltic pump followed by nine discrete samples taken at 3.5, 5, 10,25,40,65, 75, 85, and 100 min postinjection. Because the first 16 arterial samples were collected using a pump, an appropriate smearing correc tion was applied (Dhawan et aI., 1988) .
High-performance liquid chromatography (HPLC) analysis
In each of the paired FDOPA/PET studies, the specific time course of plasma activity for FDOPA and its princi pal metabolite, 30MFD, was measured using HPLC with radiochemical detection. The five blood samples taken at 10, 25, 40, 65, and 85 min postinjection were centrifuged in order to separate plasma for HPLC. The details of the HPLC analysis are described elsewhere (Eidelberg et aI., 1993; Firnau et aI., 1988) . Two major peaks correspond ing to FDOPA and 30MFD were distinguished; a small peak from an unknown metabolite was also observed overlapping the FDOPA peak. A chromatography curve fitting program ("Peakfit", Jandal Scientific, San Rafael, CA, U.S.A.) was employed to separate the peaks and calculate the ratio of area under curves for FDOPA and its metabolites.
We assessed the pharmacokinetics of FDOPA by cal culating the pharmacokinetic circulation time, OTFD (OTFD = J� CaFD (t)dt/CaFD (T», where CaFD (t) is the radio activity concentration of FDOPA in plasma as a function of time and CaFD (T) is the concentration at specific time, T. This paramete:r indicates the time needed for a bolus delivered substance to achieve the same availability achieved by maintaining the plasma concentration con stant (Gjedde, 1981) . We also calculated an index of phar macokinetic efficiency, Ep[Ep = (T/OTFD) x 100%], where 0T FD is the pharmacokinetic circulation time at specific time, T (Guttman et aI., 1993) .
Image analysis
Region of interest (ROI) analysis was performed on 256
x 256 PET reconstructions using a S UN microcomputer (490 SPARC Server, Sun Microsystems, Mountain View, CA, U.S.A.) and ScanIVP software (Spetsieris et aI., 1993) . Striatal and occipital ROIs were identified by visual inspection with reference to a standard neuroana tomic:al atlas (Talairach and Tournoux, 1988) . Elliptical ROIs were placed so as to encompass the whole striatum (mean 90 pixels/striatum; pixel size 4 mm 2 ), and identical ROI size was used for the two studies in the same subject. Background count rates were determined separately for an occipital ROI (mean size 350 pixels), which was placed on composite PET slices with reference to the first lO-min scan so as to avoid activity in the transverse sinuses and torcula. Kinetic measures for the striatal FDOPA uptake were calculated graphically by the multiple time graphical ap proach (MTGA) (Patlak et aI., 1983; Patlak and Blasberg, 1985) using the time course of striatal radioactivity and each of two input functions. The first input function for plasma FDOPA was determined using plasma arterial blood sampling and HPLC analysis as described above. The time course of specific (background subtracted) stri atal concentration divided by plasma FDOPA activity was plotted against the ratio of the plasma time integral to the plasma FDOPA concentration. In the MTGA, the slop.: of the line represents the rate constant of FDOPA uptake into the striatum, KtD (Eidelberg et aI., 1993) . Striatal uptake rate constants obtained in this way were designated KtD (Eidelberg et aI., 1993; Takikawa et aI., 1994) . The second input function consisted of the time course of occipital 18F activity. In this analysis, we de termined the occipital I SF time-activity curve in serial PET images acquired over a full 100-min interval begin ning at the time of injection. The time course of striatall occipital activity was plotted against the ratio of inte grat.:d occipitaHo-occipital activity to obtain striatal Kj valw�s, designated KjOCC (Brooks et aI., 1990; Takikawa et aI., 1994) . We determined striatal DDC activity by two methods. For the first method, we previously found that values of striatal DDC activity estimated from population mean values of 30MFD transport rate constants (designated k3 D (pop» are significantly correlated with the actual k3 D values calculated using individual subject KIM and k2M values obtained with adjunctive 30MFDIPET (Ishikawa et all., 1996) . We therefore employed population mean KIM and k2M values [KIM = 0.0400 (ml/min/g), k2M = 0.0420 (min -I ) for striatum; K\ M = 0.0371, k2 M = 0.0468 for frontal cortex; KI and k2 are the unidirectional blood brain and fractional brain-blood clearances for FDOP A and 30MFD (with superscripts D and M, respectively) (see Fig. 1 )] for the calculation of striatal k3 D (pop) in this study. In our four-compartment model (Dhawan et aI., 1996) , we set the values of ksD, k7D, and k9D all to 0 min -
k7D is the'lumped O-methylation and oxidation coefficient oftluorodopamine (FDA), and k9D is the fractional clear ance from brain of diffusible FDA metabolites (see Fig.  1 )] and estimated frontal and striatal KID, k2D, k3D (pop), and Vb' the brain vascular volume. In a second compart mental modeling approach, we used the model of Kuwa bara et aI., 1993 (Model M2) and estimated striatal KID, k3 D (M2), and Vb with several predetermined q values (q = KIM/KID = 0.5, 1.0, 1.7,2.3, and 3.0). These q values were selected based on the following estimates: 2.3 (Reith et aI., 1990 ), 1.7 (Huang et aI., 1991) , and 1.0 (based on our combined 30MFD and FDOPA/PET measurements). These calculations were performed using software for the statistical analysis of nonlinear models (PCNONLIN, SCI Software, Lexington, KY, USA). Based on the striatal kinetic rate constants [KID, k2D, k3D (pop)] estimated from our model, we calculated the following measures: The striatal distribution volume of
, the fraction of FDOPA that proceeds towards FDA synthesis fro DA = k3D/(kzD + k3D)], and the distribution volume of FDOPA that participates in FDA synthesis ( f't0 D A ) . We also calculated composite rate constants of FDOPA uptake: KD and KD' [KD = KID X k3D/(k2D + k3D); KD' = k2D X k3D/(k2D + k3D)] (Patlak and Blas berg, 1985) . In addition to the above kinetic analysis, we also cal culated the striato-occipital ratio (SOR) by dividing striatal count rat, es by occipital count rate measured on the last IO-min scan (90-100 min postin jection).
Statistical analyses
The following statistical procedures were performed using SAS (SAS Institute; Cary, NC, U.S.A.): (a) The mean % fraction of plasma FDOI' A metabolites were compared with and without OR-611 pretreatment using repeated measures analysis of variance (ANOY A). 6 T FD and Ep values were also compared with and without OR-611 using the paired Student's (-test. (b) 
RESULTS
Plasma analysis
Without COMT inhibition, 30MFD is the pre dominant metabolite at 20-30 min (Fig. 2, left  panel) . At 85 min postinjection, the fraction of 30MFD reached 70% and the fraction of FDOPA decreased to <20%. An average . of 10% of the total radioactivity was from an unknown metabolite. With OR-611 ( Fig. 2, right pane!) ., the 30MFD frac tion was significantly inhibited to <20% at the end of the study (p < 0.001). The FDOPA fraction, by contrast, increased significantly (0 < 0.01), remain-ing >50% throughout the study. The fraction of the unknown metabolite increased significantly to 30% after 30 min (p < 0.05). Overall, the mean propor tion of FDOPA in plasma at 85 min increased from 17 to 50% through the use of OR-611.
The values of the pharmacokinetic circulation time of FDOPA, STFD, and the pharmacokinetic ef ficiency, Ep' with and without OR-611 appear in Table I . Mean STFD decreased significantly from 271.0 to 146.7 min (p < 0.001), and mean Ep in creased significantly from 21 .2 to 37.7% with OR-611 pretreatment (p < 0.001).
PET analysis
Mean values and SD for SOR, striatal KtD, K?CC, k3D (pop), and kt (M2) calculated for sev eral q values are given in Table I ever, significantly increased in all cases with OR-611 premedication (mean change 53.5%, p < 0.01). SOR was increased by an average of 21.8% with OR-611 pretreatment (p < 0.05), due to a 3% in crease in the proportion of the injected dose within the striatum and a 13% decrease in the proportion of the injected dose in the occipital cortex.
With regard to striatal DDC activity, k3D (pop) did not show significant change with OR-611 pre treatment. On the other hand, k3 ° (M2) values de creased by pretreatment for all q � 1.7 (p < 0.05).
With OR-611 pretreatment, k3D (M2) values were variable at all choices of q, as compared with values obtained without COMT inhibition. Ve, the partition volume of FDOPA, did not show significant change with or without OR-611 in either frontal cortex or striatum. Ve values in the striatum were observed to be higher than those in the frontal cortex by an average of 20%, irrespective of treatment status (Fig. 4) . Error bars represent :c 1 SD. The 30M FD fraction was significantly inhibited with OR-611 (OR-611) preadministration to <20% at the end of the study (p < 0.001). By contrast, the FDOPA fraction in creased significantly (p < 0.01) with OR-611, being maintained at >50% throughout the study. With OR-611 pretreatment, the fraction of the unknown metabolite(s) in creased significantly to 30% after 30 min (p < 0.05). None of the calculated functional indexes, such as V str L"D O P A ro D A V to D A KD or KD' showed e ,l� , 'e " , significant change with OR-611 preadministration (Table 2) . Changes in KD and KD' values are pre sented in Fig. 5 . KD values are highly correlated with KtD with and without OR-611 (r = 0.88 and 0.75 for the treated and untreated states, respec tively; p < 0.0] for both correlations) ( Fig. 6, left panel). KD' values correlated significantly with K j O CC values for both treatment conditions (r = 0.61 and 0.60, respectively; p < 0.05 for both). However, the slopes of the regression lines between K? C C and K D' tended to be different in the two treatment states (36.1 % difference, p = 0.06) ( Fig.  6, right panel) .
DISCUSSION
Plasma analysis
There has been much interest in the adjunctive use of COMT inhibitors with L-dopa therapy for PD. OR-611 acts predominantly by inhibiting COMT at peripheral sites, such as liver, kidney, gut, and red blood cells (Linden et aI., 1990) . This compound was found to effectively increase the half life of L-dopa and reduced the formation of 30MFD in cynomolgus monkeys (Cedarbaum et aI., 1991; Guttman et aI., 1993) . We administered OR-611 to PD patients and found that this medication effec tively reduced the metabolism of FDOPA to 30MFD and prolonged the plasma half-life of FDOPA. Our findings are consistent with those of the analogous animal experiment in which COMT inhibition with OR-611 reduced the 30MFD frac tion to 15% at 60 min (Guttman et aI., 1993) . These investigators also detected an unknown metabolite, perhaps dopamine sulfate, that accounted for 10% of plasma activity at 60 min. In our human study, we found a lower FDOPA fraction at 60 min as J Cereb Blood Flow Metab, Vol. 16, No_ 5. 1996 compared to that in the monkey experiments (55% as compared with 75%, respectively). This was due, presumably, to an increase in the fraction of the unknown metabolite (30% as compared with 10%, respectively), rather than to a change in the 30MFD fraction, which did not differ between the two studies. FDA is deaminated by monoamine ox idase to 3,4-fluoro-dehydroxyphenylacetic acid (FDOPAC). FDA undergoes 3-0-methylation by COMT to 3-methoxytyramine and is subsequently conjugated by phenosulfotransferase to 6-fluoro dopamine sulfate. FDOP AC can also undergo 3-0methylation by COMT to 6-fluorohomovanillic acid (FVHA). With COMT inhibition, the metabolic pathways from FDA to FDA sulfate and from FDOPAC to fluorovanillic acid (FV A) are also blocked, which may result in a relative increase of FDOPAC. However, the location of the peak in HPLC suggests that it may be assigned to 6-FDA sulfate rather than to FDOPAC (Firnau et aI., 1988) . A full HPLC analysis with comparison to known standards will be needed to conclusively identify this metabolite, but for modeling purposes, it is im portant to know that none of these metabolites cross the blood-brain-barrier (BBB).
When we estimated the pharmacological circula tion time, 8TFD, the value significantly decreased with OR-611 pretreatment. The pharmacological ef ficiency of FDOPA, E rf FD, increased significantly with OR-61 1. Both 8TF and E/D changes are con sistent with the corresponding values from the mon key study (Guttman et aI., 1993) . OUI' results, there fore, demonstrate that OR-611 is effective in pro longing the available time of FDOPA in plasma in PD patients.
SOR
In their monkey study, Guttman et ai. (1993) demonstrated, using FDOPA/PET, that administra- tion of OR-611 increased striatal radiotracer accu mulation with 20% increase in the striatum/occipital cortex ratio. Subsequently, stud ied six normal subjects and four PD patients and found a mean increase in (striatum-occipital)/ occipital ratio of � 38%, due to a combination of 22% increase in the proportion of the injected dose present within the striatum and an II % decrease in the proportion of the injected dose in the cerebel lum at 90 min postinjection. In our study, we noted an increase of 20% in SOR due to the combination of a 3% increase in the proportion of the injected dose within the striatum and a I! 3% decline in that proportion in the occipital cortex . This finding agrees with Sawle's data, which, if also calculated as the striatum/occipital ratio, corresponds to a 19% increase with OR-61 I. The decline in the occipital cortex appears to have resulted from the �20% in crease of the unknown metabolite, probably 6-FDA sulfate, which does not cross the BBB. OR-61 I pre treatment thus gives rise to a net reduction in the combined FDOPA and 30MFD plasma fraction, and lowers the total activity in "neutral" brain re gions such as the occipital cortex. This decrease in the occipital cortex appears to play a greater role in raising SOR than does a concomitant increase in striatal FDOPA concentration. The discrepancy be tween Sawle's data and ours regarding the percent contribution of striatal and occipital activities to the �n � rease in SOR probably stems from the way the mJected dose was estimated. We estimated this in jected dose by normalizing it by body weight (the procedure used by Sawle was not published). Be cause of the short study duration and slow uptake of tracer in the striatum of PD patients, the striatal increase with OR-611 may be smaller than that in a comparable study of larger duration (>200 min).
DOC activity (k3 D) Guttman et al. (1993) estimated striatal DDC ac tivity by the method of Kuwabara et al. (1993) , in which a fixed ratio, q, was assumed for the trans port kinetic rate constants for FDOPA and 30MFD (KjM/KjD). They selected q = 2.3 based on data derived from rat experiments (Reith et aI., 1990) . These investigators found that striatal k3 D (M2) fell fr � m 3.9 to 2.5 (h -I) following OR-611, although thiS decrease did not reach statistical significance (Guttman et aI., 1993) .
When we applied Kuwabara's model (M2) with choices of q to our patient data, estimates of striatal k3 D (M2) significantly decreased after OR-61 I pre treatment, but only when q values � 1.7 were se lected. However, neither k3 D (M2) values estimated with q values <1.0 nor k3D (pop) values showed significant change with COMT inhibition. We also t h . D no e t at m our study k3 (M2) values were found to be sensitive to the choice of q, especially when �OMFD .
was present appreciably in plasma. Specif Ically, without COMT inhibition, model M2 with q � 1.7 produces a significant increase in k2 D, with a compensatory increase in the estimated k3 D (M2) value. A large q value causes an artificial increase in the size of the 30MFD pool relative to the free FDOPA pool. This forces a compensatory increase in k3D to keep the size of the bound FDOPA pool constant and is primarily dependent on the shape of the brain curve during the later scan times. When the plasma 30MFD fraction was reduced with OR-611
. p � etreatment, k3D (M2) did not vary with q. AdditIonally, that model assumed a common value for frontal and striatal Ve' However, our data re vealed a 20% difference in Ve values between the frontal cortex and striatum. The constraint of a common value for .
the frontal and striatal Ve may also lead to overestimation of k2 D values in the stri atum, with a compensatory overestimation in stri atal k3D (M2) values. We conclude that model M2 may be sensitive to the choice of q and that the assumption that Ve is equal in frontal cortex and striatum may be invalid. These assumptions may lead to a q-dependent overestimation of k3 D (M2) in the presence of a large 30MFD plasma fraction and, consequently, a spurious decline in striatal k D (M2) with COMT inhibition. Indeed, animal studi�s have demonstrated that OR-611 does not cross the BBB � nd does not effect central DDC activity (Manmsto et aI., 1992) . For this reason, we con clude that this model may not be appropriate for DDC activity estimation in settings in which COMT is not effectively inhibited.
According to Patlak and Blasberg (1985) , free FDOPA is the fraction of the amount in the revers �ble compartments that leaves the system by return mg to plasma. The free FDOPA fraction (m O P A ) is, therefore, calculated as k2 Dj(k2 D + k3 D). Similarly, the fraction and distribution volume of FDOPA that participate in FDA synthesis (rO D A and ve t o FD) can be expressed as k3 Dj(k2 D + k3 D) and ft o D A X Ve str , respectively. When we calculated the striatal distri bution volume of FDOPA, Ve str and fDO PA based on the kinetic rate constants derived by our model, we found no significant change with OR-611 pretreat ment. In addition, we found no significant change in estimates of ro D A and veto D A with OR-611 treat ment. These findings support the lack of a central effect of OR-611 on dopamine metabolism.
FDOPA influx rate constants
We found no change in KtD with OR-611. This finding is consistent with the animal experiment of Vol. 16, No.5, 1996 E(-) E(+) Guttman et al. (1993) , who calculated striatal influx rate constants for FDOPA, KtD, and found no change in this parameter with OR-611 pretreatment. Similarly, found no change in KtD values in humans. We did find that KiOCC in creased significantly by �50% with OR-611 pre treatment, in agreement with the findings of . These investigators speculated that the reason for the KiOCC increase was its sensitivity to the presence of 30MFD in the periphery, and sug gested that the change in free brain FDOPA may be reflected in the magnitude of change in the value of KiOCC• We did not, however, find a significant in crease in the free brain FDOPA fraction, [D O PA , in our kinetic analysis (see above). We also used the individually estimated rate constants" KID, k2D, and Frontal Striatum function such as K j O CC should be correlated to KD', assuming metabolites can be neglected in the refer ence region (Patlak and Blasberg, 1985) . Indeed, we found that K D ' correlated significantly with K? CC irrespective of treatment status. Nevertheless, the slope of the regression line of the data with COMT inhibition tended to be different from those without pretreatment (Fig. 6 ). Furthermore, mean K j O CC was elevated significantly with OR-611, while K D '
was not significantly changed. As mentioned above, our data suggest that the increase in the plasma con centration of the sulfated metabolite with OR-61 I Neither of these two macroparameters changed significantly with OR-611 preadministration. for treated and untreated states, re spectively; p < 0.05 for both corre lations). However, the slopes of the regression lines for this correlation tended to be different in the two treatment states (p = 0.06). the combined FDOPA and 30MFD plasma frac tion. This, in turn, gives rise to a reduction in "neu tral" region brain count rates. Such reductions in the occipital time-activity integral serve to increase Kj O CC, without necessarily affecting striatal FDOPA uptake. We note that striatal K j O CC values derived by graphical analysis appear not to discrim inate PD patients from normals as accurately as do KtD values determined with metabolite-corrected plasma input functions (Takikawa et aI. , 1994; Sawlie et aI. , 1994) . Similarly, we have found K?CC not to be as well correlated with clinical severity ratings (Takikawa et aI. , 1994) . These comparative limitations in K?CC may derive from inaccuracies in this estimah: introduced by variable fractions of the non transported sulfated metabolite. Nonethe less, because the range of this fraction is narrow across subjects when peripheral DDC activity is blocked by carbidopa (Melega et aI. , 1990) , K?CC remains a very useful noninvasive alternative to KtD for most clinical applications (e.g. , Brooks et aI. , 1990) .
In summary, our results suggest that OR-611 has little: effect on FDOPA kinetics in the striatum, and that the main pharmacologic effect of this agent is brought about by the prolongation of FDOPA cir culation time in plasma. This PET result is in agree ment with those of clinical studies showing that the improvement in L-dopa response duration with OR-611 was proportional to the increased half-life of L-dopa in plasma in the treated state (Mellero et aI. , 1994) . Quantitative FDOPA/PET may be useful in assessing the dfects of other pharmacologic manip ulations of L-dopa delivery in the treatment of par kinsonism.
